Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?

作者: Michael Oellerich , Victor William Armstrong

DOI: 10.1097/00007691-200202000-00008

关键词:

摘要: Cyclosporine is a critical dose drug for which individualisation by therapeutic monitoring indisputable. Current evidence suggests that single concentration (C 2 ) taken two hours after cyclosporine administration with the microemulsion formulation better predicts exposure and events than trough 0 ), routinely used adjusting dosage of this drug. Studies have shown greatest calcineurin inhibition maximum IL-2 production occur in first I to dosing. These findings support concept C level reflects immunosuppressive efficacy concentration. Preliminary data from an outcome study liver transplant recipients incidence biopsy proven moderate severe acute rejection was significantly lower patients managed compared those monitored . The importance achieving adequate during 3 5 posttransplant days prevent has been documented prospective studies de novo renal recipients. Conversion maintenance heart resulted amelioration function. Time-dependent target values proposed require further validation. For routine levels on-site validated dilution guidelines are necessary most available immunoassays. necessitates organizational requirements may be judged differently between centers. In particular early period promising new option make therapy safer more efficient.

参考文章(33)
David W Holt, Atholl Johnston, Barry D Kahan, Raymond G Morris, Michael Oellerich, Leslie M Shaw, New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clinical Chemistry. ,vol. 46, pp. 872- 874 ,(2000) , 10.1093/CLINCHEM/46.6.872
Nicolas von Ahsen, Michael Richter, Clemens Grupp, Burckhardt Ringe, Michael Oellerich, Victor W Armstrong, No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clinical Chemistry. ,vol. 47, pp. 1048- 1052 ,(2001) , 10.1093/CLINCHEM/47.6.1048
David Freeman, David Grant, Gary Levy, James Rochon, Pui-Yuen Wong, Ibrahim Altraif, Sami Asfar, Pharmacokinetics of a New Oral Formulation of Cyclosporine in Liver Transplant Recipients Therapeutic Drug Monitoring. ,vol. 17, pp. 213- 216 ,(1995) , 10.1097/00007691-199506000-00001
Marcelo Cantarovich, Eleanor Elstein, Benoit de Varennes, Jeffrey S. Barkun, Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. ,vol. 68, pp. 1839- 1842 ,(1998) , 10.1097/00007890-199912270-00003
P Belitsky, G.A Levy, A Johnston, Neoral absorption profiling: an evolution in effectiveness. Conference on Neoral Absorption Profiling. ,vol. 32, ,(2000) , 10.1016/S0041-1345(00)00863-0
M. Oellerich, V. W. Armstrong, B. Kahan, L. Shaw, D. W. Holt, R. Yatscoff, A. Lindholm, P. Halloran, K. Gallicano, K. Wonigeit, E. Schütz, H. Schran, T. Annesley, Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Therapeutic Drug Monitoring. ,vol. 17, pp. 642- 654 ,(1995) , 10.1097/00007691-199512000-00017
Victor W Armstrong, Michael Oellerich, New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine Clinical Biochemistry. ,vol. 34, pp. 9- 16 ,(2001) , 10.1016/S0009-9120(00)00175-2
Marcelo Cantarovich, Jeffrey S. Barkun, Jean I. Tchervenkov, Jean-Guy Besner, Launa Aspeslet, Peter Metrakos, Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. ,vol. 66, pp. 1621- 1627 ,(1998) , 10.1097/00007890-199812270-00009